RELAX-AHF shows first positive findings in HFpEF patients

May 26, 2013, European Society of Cardiology

Serelaxin may be more effective for relieving dyspnea in heart failure with preserved ejection fraction (HFpEF) than reduced (HFrEF) during the first 24 hours, according to results from RELAX-AHF presented in today's late breaking trial session1 at the Heart Failure Congress 2013. Results were also presented from VIVIDD, the first trial of the anti-diabetes drug vildagliptin in patients with heart failure.

The Heart Failure Congress is the main annual meeting of the Heart Failure Association of the and is being held 25-28 May in Lisbon, Portugal. Link to congress

Many with (AHF) have preserved but there is a lack of evidence based therapies for this population. In a sub-group analysis, investigators of the Relaxin in Acute Heart Failure (RELAX-AHF) trial addressed the question of whether serelaxin was equally effective in AHF patients with HFpEF and HFrEF.

RELAX-AHF was a double blinded, randomised, placebo controlled trial in which 1161 AHF patients from 96 sites were randomised to 48 hour infusion of serelaxin or placebo within 16 hours of presentation. The primary efficacy endpoint was the effect on dyspnea in the short term (6, 12 and 24 hours) and at 5 days. Secondary efficacy endpoints were or rehospitalisation for heart or , and days alive and out of hospital through day 60. All-cause death and cardiovascular death through day 180 were also evaluated.

Serelaxin induced similar dyspnea relief in HFpEF and HFrEF patients at day 5 but was more effective in the HFpEF group in the first 24 hours. There were no differences between HFpEF and HFrEF patients in the effect of serelaxin on the secondary endpoints. Serelaxin had similar benefits on mortality in patients with HFpEF and HFrEF.

Presenter Professor Gerasimos Filippatos (Greece) said: "RELAX-AHF is the first trial to give positive findings in patients with acute heart failure and preserved ejection fraction, a large population with unmet treatment needs. Seralaxin is at least as effective in AHF patients with HFpEF for relieving during the first 24 hours and had a similar effect on rehospitalisation and survival in HFrEF and HFpEF patients."

The Vildagliptin in Ventricular Dysfunction Diabetes (VIVIDD) trial investigated the effects of the DPP4 inhibitor vildagliptin in patients with type 2 diabetes and HFrEF (left ventricular ejection fraction [LVEF] <40%). It is the first study to test this class of anti-diabetes drugs in patients with heart failure.

Presenter Professor John McMurray (UK) said: "Diabetes and heart failure is a common dual problem and these patients have a particularly bad outlook. But, remarkably, are excluded from most trials testing diabetes drugs. At the moment it's not at all clear how clinicians should choose between the various anti-diabetes drugs when confronted with a heart failure patient."

The primary objective of this randomised, double-blind, placebo was to demonstrate that vildagliptin was non-inferior to placebo with respect to change in echocardiographic LVEF from baseline to 52 weeks. For the trial, 254 patients from 15 countries were randomised to 52 weeks treatment with placebo or vildagliptin 50mg bid.

The effect of vildagliptin on LVEF did not differ from placebo, confirming non-inferiority. But, unexpectedly, vildagliptin increased the size of the left ventricle with no decline in the contraction and emptying of the left ventricle and no change in B-type natriuretic peptide (BNP).

Professor McMurray said: "Normally an increase in the size of the left ventricle is associated with a decline in systolic function but we saw no change in ejection fraction and a fall rather than increase in BNP. We speculate that the surprising findings of VIVIDD indicate that this anti- may have improved the distensibility and compliance of the left ventricle."

He concluded: "We don't have enough studies investigating the effects of anti-diabetes drugs in patients with both diabetes and . The two diseases clearly interact in many ways and unless a drug is studied in these very vulnerable patients we will never know what effect it has."

Explore further: Study finds new drug may hold promise for hospitalized heart failure patients

Related Stories

Study finds new drug may hold promise for hospitalized heart failure patients

November 7, 2012
Hospitalized heart failure patients given an investigational drug had improved symptoms and other clinical benefits including fewer deaths, than those given standard of care plus a placebo, according to late-breaking clinical ...

Efficacy of LCZ696 in patients with heart failure and preserved ejection fraction

August 27, 2012
The novel angiotensin receptor neprilysin inhibitor, LCZ696, demonstrated beneficial effects in heart failure patients with preserved ejection fraction (HFpEF), according to results of the PARAMOUNT (Prospective compArison ...

Sildenafil for heart failure does not result in significant improvement in exercise capacity

March 11, 2013
Among patients with heart failure with preserved ejection fraction (a measure of heart function), administration of sildenafil (commercially known as Viagra) for 24 weeks, compared with placebo, did not result in significant ...

Common heart failure drugs could benefit more patients

November 27, 2012
A novel study from Karolinska Institutet in Sweden suggests that commonly used drugs to treat heart failure and high blood pressure may have a wider range of application than earlier known, and also can be used against so ...

Studies examine whether therapies for heart failure are associated with improved survival

November 27, 2012
An analysis of two heart failure therapies finds differing outcomes regarding improvement in survival, according to two studies appearing in the November 28 issue of JAMA.

Death highest in heart failure patients admitted in January, on Friday, and overnight

May 25, 2013
Mortality and length of stay are highest in heart failure patients admitted in January, on Friday, and overnight, according to research presented today at the Heart Failure Congress 2013. The analysis of nearly 1 million ...

Recommended for you

A nanoparticle inhalant for treating heart disease

January 18, 2018
A team of researchers from Italy and Germany has developed a nanoparticle inhalant for treating people suffering from heart disease. In their paper published in the journal Science Translational Medicine, the group describes ...

Starting periods before age of 12 linked to heightened risk of heart disease and stroke

January 15, 2018
Starting periods early—before the age of 12—is linked to a heightened risk of heart disease and stroke in later life, suggests an analysis of data from the UK Biobank study, published online in the journal Heart.

'Decorated' stem cells could offer targeted heart repair

January 10, 2018
Although cardiac stem cell therapy is a promising treatment for heart attack patients, directing the cells to the site of an injury - and getting them to stay there - remains challenging. In a new pilot study using an animal ...

Two simple tests could help to pinpoint cause of stroke

January 10, 2018
Detecting the cause of the deadliest form of stroke could be improved by a simple blood test added alongside a routine brain scan, research suggests.

Exercise is good for the heart, high blood pressure is bad—researchers find out why

January 10, 2018
When the heart is put under stress during exercise, it is considered healthy. Yet stress due to high blood pressure is bad for the heart. Why? And is this always the case? Researchers of the German Centre for Cardiovascular ...

Heart-muscle patches made with human cells improve heart attack recovery

January 10, 2018
Large, human cardiac-muscle patches created in the lab have been tested, for the first time, on large animals in a heart attack model. This clinically relevant approach showed that the patches significantly improved recovery ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.